RDHL Redhill Biopharma Ltd.

9.99
+0.1398  (1%)
Previous Close 9.85
Open 9.85
Price To book 2.84
Market Cap 169.90M
Shares 17,007,000
Volume 35,146
Short Ratio 2.31
Av. Daily Volume 57,452

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 2H 2017.
MESUPRON
Pancreatic cancer
Phase 2a trial to be initiated 2H 2017.
YELIVA
Cholangiocarcinoma
Phase 1b to be initiated 2H 2017.
YELIVA
Prevention of mucositis in cancer patients undergoing therapeutic radiotherapy
Phase 1/2 trial initiation announced September 8, 2016. Announced that dosing has commenced - December 19, 2016.
YELIVA
Refractory or relapsed multiple myeloma - cancer
Planned NDA resubmission due 3Q 2017.
RIZAPORT (RHB-103)
Migraine
Phase 3 DSMB safety analysis released December 13, 2016 - trial to continue as planned. Interim efficacy analysis due mid-2017.
RHB-104 MAP US
Crohn’s disease
Phase 3 final data released March 2016. Additional Phase 3 trial planned to be 2Q 2017.
RHB-105
H. pylori
Phase 3 enrollment closed February 13, 2017. Top-line data due 2Q 2017.
BEKINDA -GUARD
Gastroenteritis
Phase 2a data released December 12, 2016.
RHB-104 CEASE-MS
Multiple sclerosis
Phase 2 top-line data due 3Q 2017.
BEKINDA
IBS-D
Phase 2 initiated October 2016.
YELIVA
Hepatocellular carcinoma (HCC) - cancer
Phase 2 to be initiated 2H 2016
YELIVA
Mucositis in cancer patients
Phase 1/2 trial amended to include Kaposi sarcoma patients. Trial due to resume in late 2016.
YELIVA
Refractory/relapsed diffuse large B-cell lymphoma (DLBCL)

Latest News

  1. RedHill Biopharma Announces Poster Presentation of the Positive RHB-105 Phase III Results for H. pylori Infection at Digestive Disease Week 2017
  2. RedHill Biopharma Reports 2017 First Quarter Financial Results
  3. RedHill Biopharma to Host First Quarter 2017 Financial Results Conference Call on May 3, 2017
  4. RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D
  5. RedHill Biopharma Announces Peer-Reviewed Publication of the Positive YELIVA® Phase I Study Results in Advanced Solid Tumors
  6. RedHill Biopharma to Host R&D Day on BEKINDA® for Acute Gastroenteritis and IBS-D
  7. RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA®
  8. RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT® for Migraines in Luxembourg
  9. Company News for April 05, 2017
  10. RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam®
  11. RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA® for the Treatment of Cholangiocarcinoma
  12. RedHill Biopharma to Present at BioCentury Future Leaders in the Biotech Industry Conference
  13. RedHill Biopharma to Present at the 2017 MAP Conference
  14. RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn's Disease